Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Cipla Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (473)
Cancellation by sponsor (240)
Cancellation or suspension (79)
Prescription medicine registration (49)
Cancellation for failure to pay annual charge (17)
Australian Public Assessment Report (AusPAR) (5)
Prescription medicine decision summary (4)
Prescription medicine evaluation (1)

Date

2026 (28)
2025 (96)
2024 (73)
2023 (99)
2022 (70)
2021 (65)
2020 (112)
2019 (18)
2018 (68)
2017 (104)
2016 (27)
2015 (33)
2014 (13)
2013 (5)
2012 (4)
2011 (6)
2010 (16)
2009 (4)
2008 (3)
2007 (5)
2006 (2)
2005 (2)
2004 (2)
2003 (3)
2002 (2)
2001 (3)
2000 (1)
1999 (2)
1998 (1)
1996 (1)

Search

Sponsor content

868 result(s) found, displaying 371 to 380

PHARMACY ACTION PHARMISIL terbinafine hydrochloride 1% cream tube Cancelled under Section 30(1)(c) of the Act

14 June 2022

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
PHARMACY ACTION URELIEF Effervescent Granules oral powder sachet Cancelled under Section 30(1)(c) of the Act

14 June 2022

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
CIPLA HYDROCORTISONE, CORTI-H, CORTICIP, HYDROCIP (Cipla Australia Pty Ltd)

1 June 2022

Prescription medicine registration

Active ingredients: Hydrocortisone sodium succinate.
AusPAR: Bevacizumab

31 May 2022

Australian Public Assessment Report (AusPAR)

Bevacip/Bevaciptin (bevacizumab) for the treatment of types of cancer.
DEXMEDETOMIDINE CIPLA dexmedetomidine (as hydrochloride) 200 microgram/2 mL concentrated injection vial (321725)

16 June 2020

ARTG

Australian Register of Therapeutic Goods (ARTG) information for DEXMEDETOMIDINE CIPLA dexmedetomidine (as hydrochloride) 200 microgram/2 mL concentrated injection vial.
DEXMED dexmedetomidine (as hydrochloride) 200 microgram/2 mL concentrated injection vial (321727)

16 June 2020

ARTG

Australian Register of Therapeutic Goods (ARTG) information for DEXMED dexmedetomidine (as hydrochloride) 200 microgram/2 mL concentrated injection vial.
DEXEMCIP dexmedetomidine (as hydrochloride) 200 microgram/2 mL concentrated injection vial (321728)

16 June 2020

ARTG

Australian Register of Therapeutic Goods (ARTG) information for DEXEMCIP dexmedetomidine (as hydrochloride) 200 microgram/2 mL concentrated injection vial.
MENDELEEV CHILDREN’S PARACETAMOL 6 – 12 YEARS 48 mg/mL oral liquid bottle Cancelled under Section 30(1)(c) of the Act

16 May 2022

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
MENDELEEV CHILDREN’S PARACETAMOL 1 – 5 YEARS 24 mg/mL oral liquid bottle Cancelled under Section 30(1)(c) of the Act

16 May 2022

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
MENDELEEV CHILDREN’S IBUPROFEN 6 MONTHS – 12 YEARS 20 mg/mL oral liquid suspension bottle Cancelled under Section 30(1)(c) of the Act

16 May 2022

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd

Pages

First page
Previous page
…
Page 34
Page 35
Page 36
Page 37
Current page 38
Page 39
Page 40
Page 41
Page 42
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.